A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Pat… (NCT07548697) | Clinical Trial Compass
RecruitingEarly Phase 1
A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma
China24 participantsStarted 2026-04-30
Plain-language summary
This study is a single arm, open label, dose exploring clinical study to evaluate the safety, efficacy, metabolic kinetics and pharmacodynamics of CT1182 cells in patients with relapsed / refractory B-cell non Hodgkin lymphoma (r/r B-NHL).
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. According to CT measurement: the long diameter of intranodal lesions is \>1.5 cm, or the long diameter of extranodal lesions is \>1.0 cm, and the short diameter can be measured;
✓. According to PET measurement: FDG uptake score reaches 4 or 5;
✓. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN, total bilirubin ≤ 1.5 × ULN; If lymphoma invades the liver: AST and alt ≤ 5 × ULN, total bilirubin ≤ 3.0 × ULN;
✓. The international normalized ratio (INR) and activated partial thromboplastin time (APTT) should be ≤ 1.5 × ULN.
✓. Blood oxygen saturation in non oxygen inhalation state ≥ 92%;
✓. Left ventricular ejection fraction (LVEF) ≥ 50% (LVEF value is near the critical value, and can be enrolled after the investigator has fully assessed the risk);
Exclusion criteria
✕. The New York Heart Association (NYHA) cardiac function classification was grade III or IV heart failure;
✕. Myocardial infarction, unstable angina pectoris, or coronary artery bypass grafting or coronary stent implantation occurred within 6 months before screening;
✕. There is a history of clinically significant uncontrolled arrhythmias, such as ventricular arrhythmias;
What they're measuring
1
Frequency, type and severity of AES
Timeframe: Within 24 months after CT1182 infusion
2
The number and severity of dose-limiting toxicity (DLT)events
Timeframe: Within 28 days after CT1182 infusion
Trial details
NCT IDNCT07548697
SponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology